Analysts see M&A as integral to BioMarin's value creation. C...
Analysts see M&A as integral to BioMarin's value creation. Clarity on the market potential of Roctavian could stimulate transactional activities. A gene therapy division spin-off followed by a business sale is anticipated.
![](https://pubimg-10000538.picsh.myqcloud.com/20220509000003228961cde339d.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment